- Augustine Therapeutics on Wednesday announced it has raised EUR 17M ($18.5M) in the first closing of its Series A round.
- The financing was led by Asabys Partners, with participation from Eli Lilly and Company and Charcot-Marie-Tooth Research Foundation.
- The proceeds from this first close will be used to advance Augustine’s lead candidate, AGT100216, into a Phase 1/2 first-in-human clinical trial in 2025.
- The company also announced the appointment of Gerhard Koenig as executive chairman of its board.
- Press release.